Literature DB >> 17621619

Management of overactive bladder syndrome.

Sushma Srikrishna1, Dudley Robinson, Linda Cardozo, Maria Vella.   

Abstract

Overactive bladder (OAB) syndrome is the term used to describe the symptom complex of urinary urgency with or without urge incontinence, usually with frequency and nocturia. Drug treatment continues to have an important role in the management of women with OAB. Other treatment options include conservative management with lifestyle interventions, modification of fluid intake, and physiotherapy including bladder retraining. Surgery remains the last resort in the treatment and is usually reserved for intractable detrusor overactivity, as it is associated with significant morbidity. This article reviews the management of the overactive bladder with specific focus on newer developments in the medical treatment of OAB in women.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17621619      PMCID: PMC2600101          DOI: 10.1136/pgmj.2007.057232

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  79 in total

1.  Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group.

Authors:  R A Schmidt; U Jonas; K A Oleson; R A Janknegt; M M Hassouna; S W Siegel; P E van Kerrebroeck
Journal:  J Urol       Date:  1999-08       Impact factor: 7.450

Review 2.  The overactive bladder: pharmacologic basis of drug treatment.

Authors:  K E Andersson
Journal:  Urology       Date:  1997-12       Impact factor: 2.649

3.  Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study.

Authors:  L Rentzhog; S L Stanton; L Cardozo; E Nelson; M Fall; P Abrams
Journal:  Br J Urol       Date:  1998-01

4.  Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity.

Authors:  R Millard; J Tuttle; K Moore; J Susset; B Clarke; P Dwyer; B E Davis
Journal:  J Urol       Date:  1999-05       Impact factor: 7.450

5.  Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia--a double-blind, placebo-controlled clinical trial.

Authors:  M Stöhrer; H Madersbacher; R Richter; J Wehnert; K Dreikorn
Journal:  Spinal Cord       Date:  1999-03       Impact factor: 2.772

6.  Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group.

Authors:  R U Anderson; D Mobley; B Blank; D Saltzstein; J Susset; J S Brown
Journal:  J Urol       Date:  1999-06       Impact factor: 7.450

7.  Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.

Authors:  R A Appell
Journal:  Urology       Date:  1997-12       Impact factor: 2.649

Review 8.  Tolterodine.

Authors:  C J Hills; S A Winter; J A Balfour
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

9.  Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions.

Authors:  M de Sèze; L Wiart; P A Joseph; J P Dosque; J M Mazaux; M Barat
Journal:  Neurourol Urodyn       Date:  1998       Impact factor: 2.696

10.  Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.

Authors:  P Abrams; R Freeman; C Anderström; A Mattiasson
Journal:  Br J Urol       Date:  1998-06
View more
  8 in total

Review 1.  Fesoterodine for overactive bladder: A review of the literature.

Authors:  Kanchan Gupta; Kirandeep Kaur; Baldev Singh Aulakh; Sandeep Kaushal
Journal:  Curr Ther Res Clin Exp       Date:  2010-10

Review 2.  Voiding dysfunction in the female patient: is the "syndrome" paradigm valid?

Authors:  Hari Siva G R Tunuguntla; Renuka Tunuguntla; Joseph Barone; Prashanth Kanagarajah; Angelo E Gousse
Journal:  Curr Urol Rep       Date:  2011-10       Impact factor: 3.092

Review 3.  Nocturia × disturbed sleep: a review.

Authors:  Daniele Furtado; Helena Hachul; Monica L Andersen; Rodrigo A Castro; Manoel B Girão; Sergio Tufik
Journal:  Int Urogynecol J       Date:  2011-08-17       Impact factor: 2.894

4.  Does conservative management really benefit patients with OAB?

Authors:  Philip E V Van Kerrebroeck
Journal:  Curr Urol Rep       Date:  2012-10       Impact factor: 3.092

5.  Women's perspective of botulinum toxin treatment for overactive bladder symptoms.

Authors:  G Alessandro Digesu; Demetri Panayi; Caroline Hendricken; Michelle Camarata; Ruwan Fernando; Vikram Khullar
Journal:  Int Urogynecol J       Date:  2010-11-24       Impact factor: 2.894

Review 6.  Advances in Assistive Electronic Device Solutions for Urology.

Authors:  Kieran Holmes-Martin; Minghui Zhu; Shujun Xiao; Faezeh Arab Hassani
Journal:  Micromachines (Basel)       Date:  2022-03-30       Impact factor: 3.523

7.  PATTERN OF OVERACTIVE BLADDER IN SOUTHEAST NIGERIA.

Authors:  A C Odoemene
Journal:  J West Afr Coll Surg       Date:  2014 Jul-Sep

Review 8.  Update on the management of overactive bladder.

Authors:  Christina Fontaine; Emma Papworth; John Pascoe; Hashim Hashim
Journal:  Ther Adv Urol       Date:  2021-08-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.